ALNY241220C400000
- 1.75
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
FDA Begins Review of Alnylam's SNDA for Expanded Amvuttra Use
Scotiabank Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $384
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $275
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
Sector Update: Health Care Stocks Edge Higher Premarket Monday
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
Express News | Alnylam Pharmaceuticals Inc - Vutrisiran Shows Encouraging Safety and Tolerability
Express News | Alnylam Pharmaceuticals Inc - FDA Sets Pdufa Date for Vutrisiran on March 23, 2025
Express News | Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of Attr Amyloidosis With Cardiomyopathy
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Alnylam Pharmaceuticals Announces Interim Phase 1 Data of Nucresiran
Express News | Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose